{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:02:00Z","timestamp":1740124920259,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41433-024-03275-y","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T15:02:11Z","timestamp":1722697331000},"page":"3272-3278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-9791","authenticated-orcid":false,"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-6079","authenticated-orcid":false,"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Hilely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sengul","family":"Ozdek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin Baran","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7439-2081","authenticated-orcid":false,"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"3275_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.","journal-title":"Eye Vis"},{"key":"3275_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4239\/wjd.v4.i6.231","volume":"4","author":"JF Arevalo","year":"2013","unstructured":"Arevalo JF. Diabetic macular edema: current management 2013. World J Diabetes. 2013;4:231\u20133.","journal-title":"World J Diabetes"},{"key":"3275_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/2042018813512360","volume":"4","author":"DS Boyer","year":"2013","unstructured":"Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151\u201369.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"3275_CR4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38:2293\u20132300.","journal-title":"Retina"},{"key":"3275_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","volume":"138","author":"PK Roberts","year":"2020","unstructured":"Roberts PK, Vogl WD, Gerendas BS, Glassman AR, Bogunovic H, Jampol LM, et al. Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: a post hoc analysis of a randomized clinical trial. JAMA Ophthalmol. 2020;138:945\u201353.","journal-title":"JAMA Ophthalmol"},{"key":"3275_CR6","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","volume":"38","author":"SB Bressler","year":"2018","unstructured":"Bressler SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5-Year Report. Retina. 2018;38:1896\u2013904.","journal-title":"Retina"},{"key":"3275_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamaophthalmol.2019.6035","volume":"138","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Baker CW, Beaulieu WT, Bressler NM, Punjabi OS, Stockdale CR, et al. DRCR Retina Network. Assessment of the DRCR retina network approach to management with initial observation for eyes with center-involved diabetic macular edema and good visual acuity: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2020;138:341\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"3275_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.oret.2019.06.016","volume":"3","author":"A Sharma","year":"2019","unstructured":"Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Loewenstein A, et al. Subfoveal neurosensory detachment flattening and observe (SNF-Ob): a novel approach in diabetic macular edema management: a potential cost-effective treatment strategy to be explored. Ophthalmol Retin. 2019;3:1009\u201311.","journal-title":"Ophthalmol Retin"},{"key":"3275_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","volume":"122","author":"R Sophie","year":"2015","unstructured":"Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology. 2015;122:1395\u2013401.","journal-title":"Ophthalmology"},{"key":"3275_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0420.2005.00387.x","volume":"83","author":"H Ozdemir","year":"2005","unstructured":"Ozdemir H, Karacorlu M, Karacorlu S. Serous macular detachment in diabetic cystoid macular oedema. Acta Ophthalmol Scand. 2005;83:63\u20136.","journal-title":"Acta Ophthalmol Scand"},{"key":"3275_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.oret.2019.03.015","volume":"3","author":"JF Korobelnik","year":"2019","unstructured":"Korobelnik JF, Lu C, Katz TA, Dhoot DS, Loewenstein A, Arnold J, et al. Effect of baseline subretinal fluid on treatment outcomes in VIVID-DME and VISTA-DME studies. Ophthalmol Retin. 2019;3:663\u20139.","journal-title":"Ophthalmol Retin"},{"key":"3275_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/IAE.0000000000000770","volume":"36","author":"KH Seo","year":"2016","unstructured":"Seo KH, Yu SY, Kim M, Kwak HW. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina. 2016;36:588\u201395.","journal-title":"Retina"},{"key":"3275_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","volume":"33","author":"M Shimura","year":"2013","unstructured":"Shimura M, Yasuda K, Yasuda M, Nakazawa T. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina. 2013;33:740\u20137.","journal-title":"Retina"},{"key":"3275_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3341\/kjo.2017.0117","volume":"32","author":"M Kaya","year":"2018","unstructured":"Kaya M, Karahan E, Ozturk T, Kocak N, Kaynak S. Effectiveness of intravitreal ranibizumab for diabetic macular edema with serous retinal detachment. Korean J Ophthalmol. 2018;32:296\u2013302.","journal-title":"Korean J Ophthalmol"},{"key":"3275_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00442-z","volume":"11","author":"JW Kwon","year":"2021","unstructured":"Kwon JW, Kim B, Jee D, Cho YK. Aqueous humor analyses of diabetic macular edema patients with subretinal fluid. Sci Rep. 2021;11:20985.","journal-title":"Sci Rep"},{"key":"3275_CR16","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. DRCR Retina Network. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880\u201394.","journal-title":"JAMA"},{"key":"3275_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"RK Maturi","year":"2018","unstructured":"Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136:29\u201338.","journal-title":"JAMA Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03275-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:04:06Z","timestamp":1732273446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03275-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":17,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03275-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS: consultant: for Novartis, Allergan, Bayer, Lupin, Intas, Biogen. TW: None. CDR- consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Bausch and Lomb, Boehringer-Ingelheim, Clearside, Eyepoint, Genentech\/Roche, Iveric, Janssen, Kodiak, Merck, NGM, Novartis, Ocugen, Opthea, Regenxbio, Stealth, Thea, Zeiss and receives research support from 4DMT, Adverum, Allergan, Annexon, Apellis, Eyepoint, Genentech\/Roche, Iveric, Janssen, Kodiak, NGM, Novartis, Ocugen, Opthea, Regenxbio, Regeneron. CMGC: Novartis, Bayer, Roche, Boehringer-Ingelheim, Topcon, Zeiss and Chui Ming Gemmy Cheung is a member of the Eye editorial board. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. DZ: consultant for Novartis, Abbvie, Bayer and Roche. DG: None. AH: None. SO: consultant for Novartis, Allergan, Bayer, Bauch & Lomb. HB\u00d6: None. NP: None. NK: None. BDK: CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. FB: consultant: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. GQ: consultant: Alimera Sciences, Allegro, Allergan Inc, Amgen, Bayer Shering-Pharma, Baush & Lomb, Boehringer-Ingelheim, CenterVue, Heidelberg, KBH, LEH Pharma, Lumithera, Nevacar, Novartis, Roche, Sandoz, Sifi, Sooft-Fidia, Topcon, Thea, Zeiss.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}